Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardiologists Push Back On Proposed Transcatheter Valve Credentialing Proposals

This article was originally published in The Gray Sheet

Executive Summary

Clinicians say some of the procedural experience requirements proposed by CMS and societies as prerequisites for conducting transcatheter aortic valve replacements might overly limit access to the technology. ACC has made some revisions to its proposal in response.

You may also be interested in...

Medical Device Market & Industry Briefs, August 2012

Brief summaries of recent medtech market and industry developments. This month we cover continuing pressures on the DES and ICD markets, update Edwards’ efforts to roll out its Sapien device for TAVR, and report on QLT’s decision to sell its punctal plug technology.

Edwards’ Sapien Ramp-Up Successful, But Medicare Policy Makes For Some Hurdles

Edwards’ rate of training hospitals on its new transcatheter valve procedure is on track with its goals but slower than the 20-site-per-month rate that the firm says it can handle, likely because some hospitals are struggling to ensure that they meet new Medicare coverage requirements.

Washington Roundup, May 2012

The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we report on the new Medicare coverage policy for transcatheter aortic valve replacement and Medicare latest hospital inpatient payment proposal.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts